{"entity":{"id":"nct03722420","kind":"trial","name":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)","aka":[],"tldr":"A phase 3 trial of Imatinib in chronic myeloid leukaemia, run by Il-Yang Pharm. Co., Ltd., active and no longer recruiting.","summary":"Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China) is a phase 3 interventional study registered as NCT03722420 by Il-Yang Pharm. Co., Ltd., with 238 participants enrolled, started 2018-12-28 and due to reach its primary completion in 2023-03-03. Interventions recorded: Radotinib and Imatinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03722420","url":"https://clinicaltrials.gov/study/NCT03722420"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cml"],"sections":[],"technologies":[],"targets":[],"drugs":["imatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03722420","phase":"3","setting":"A Phase III, Multi-center, Open-Label, Randomized Study of the Efficacy of Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Chinese Patients in Chronic Phase","sponsor":"Il-Yang Pharm. Co., Ltd.","enrolled":238,"outcomes":[]},"route":"/trials/nct03722420/","neighbours":{"cancer":[{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"radotinib","kind":"drug","name":"Radotinib","route":"/drugs/radotinib/"}]}}